ReviewFrontiers in pharmacology2023
Current drugs for HIV-1: from challenges to potential in HIV/AIDS.
Review in Frontiers in pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- Free antiretrovirals as a key tool against the HIV pandemic: A systematic review.HIV medicine · 2025Pooled it
- A Comparative Evaluation Framework Integrating Machine Learning and Deep Learning Models with ADME-Based Pharmacokinetic Assessment for HIV-Related Compounds.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Nanoparticle Vaccine Based on S1 Domain of Porcine Epidemic Diarrhea Virus Elicits Protective Immune Responses in Mice and Pigs.Biomolecules · 2026Article
- SERINC3 promotes osteogenic differentiation of BMSCs via IL-32/AMPK-mediated autophagy and mitochondrial energy metabolism.Stem cell research & therapy · 2026Article
- A Review on Medicinal Chemistry and Biological Activity of Dihydropyrimidinones Against HIV.Archiv der Pharmazie · 2026Review
- Effectiveness and safety of ainuovirine plus lamivudine and tenofovir DF in virologically suppressed people living with HIV-1: the 48-week results of a multicenter, real-world study.Antimicrobial agents and chemotherapy · 2026Observational
- Antiviral drug discovery and development: challenges and future directions.Signal transduction and targeted therapy · 2026Review
- Review
- Conquering viral drug resistance: Structural and mechanistic paradigms for antiresistance drug design.Pharmaceutical science advances · 2025Review
- Machine learning-based prediction of bioactivity in HIV-1 protease: insights from electron density analysis.Future medicinal chemistry · 2024Article
- New Therapies and Strategies to Curb HIV Infections with a Focus on Macrophages and Reservoirs.Viruses · 2024Review
- Treatment Management Challenges in Naïve and Experienced HIV-1-Infected Individuals Carrying the M184V Mutation.Viruses · 2024Review
- ROS Chronicles in HIV Infection: Genesis of Oxidative Stress, Associated Pathologies, and Therapeutic Strategies.Current issues in molecular biology · 2024Review
- Structural elucidation of HIV-1 G-quadruplexes in a cellular environment and their ligand binding using responsiveChemical science · 2024Article
- Harnessing the power of bee venom for therapeutic and regenerative medical applications: an updated review.Frontiers in pharmacology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The human immunodeficiency virus (HIV) persists in latently infected CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.